- Home
- FNLC vs PBYI Comparison
FNLC vs PBYI Comparison
Compare FNLC & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNLC | PBYI |
|---|---|---|
| Founded | 1864 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.7M | 263.4M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | FNLC | PBYI |
|---|---|---|
| Price | $26.33 | $5.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 20.9K | ★ 380.6K |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 5.60% | N/A |
| EPS Growth | 18.07 | ★ 59.87 |
| EPS | ★ 2.81 | 0.74 |
| Revenue | $88,119,000.00 | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.41 | ★ $7.99 |
| Revenue Growth | ★ 12.70 | N/A |
| 52 Week Low | $22.11 | $2.58 |
| 52 Week High | $28.60 | $6.27 |
Technical Indicators
Market Signals| Indicator | FNLC | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 44.37 | 54.93 |
| Support Level | $26.20 | $5.81 |
| Resistance Level | $26.73 | $6.27 |
| Average True Range (ATR) | 0.46 | 0.24 |
| MACD | -0.21 | -0.00 |
| Stochastic Oscillator | 6.97 | 37.97 |
Price Performance
Historical ComparisonAbout FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.